Yes, but they haven't (yet) pursued a similar dosing for any other tumor types as they have in 1L NSCLC, even ones with "weaker" patients than melanoma. For example, in SCLC they went with a Yervoy dose of 3 mg/kg Q3W for 4 doses.
If the "lower and less frequent" dosing strategy pans out in 1L NSCLC, I wouldn't surprised to see them expand it into other tumor types, but it's worth noting it's very much the exception to the rule right now, both for BMY & AZN.
Market Data 
Markets 
AI
